Últimas noticias sobre NovoCure (NASDAQ:NVCR) Bolsa

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

WIIM

GDOT

Green Dot Corp shares are trading lower after Keefe, Bruyette & Woods cut its price target on the stock from $12 to $10.

Trading Ideas

ACON

Aclarion Shares Resume Trade, Stock Now Up 80%

<p><iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" frameborder="0" height="315" src="https://www.youtube.com/embed/WlLZvB5BQw4?si=FNCgXqukTkEqw9jG" width="560"></iframe></p>
<p>January 2025 was a solid U.S. share returns month. In fact, the last 2 years delivered exceptional annual returns years for U.S. share indices. Our Chief Equity Strategist and Economist, John Blank, is here now to help us understand what&#39;s driving this.</p>
<p>1. What is the main market driver for the solid stock market returns?</p>
<p>2. After two fast paced years, the market seems like it&#39;s taking it a bit easier this year. Is it or am I imagining that?</p>
<p>3. What risks has the stock market priced in?</p>
<p>4. Are there any that it hasn&#39;t priced in yet?</p>
<p>5. Is the market too expensive now?</p>
<p>6. You made a point of writing this in your monthly market strategy, <em>&quot;</em>A legacy from excessive money printing drives stock prices, over projections for EPS growth.&quot; Why is that important to note?</p>
<p><em>7. </em>Nvidia reported their earnings yesterday. Investors had been concerned leading up to the report that the report might bring volatility back to the market in addition to what tariff news is bringing. Is that likely?</p>
<p>8. What are you looking for the stock market&#39;s annual return to be this year or is it too early to say?</p>
<p>9. Strong Buy stocks you&#39;re looking at include <strong>CrowdStrike </strong>CRWD, <strong>Citigroup </strong>(<strong>C</strong>) and <strong>Amphenol </strong>APH.</p>
<p>Our Chief Equity Strategist and Economist, John Blank, on solid stock market returns. With John, I&#39;m Terry Ruffolo.</p>
<p>&nbsp;</p>
<h2>5 Stocks Set to Double</h2>
<p>Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.</p>
<p>Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.</p>
<p><a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1726&amp;adid=SYND_BENZ_ZU_5S2DREPORT_SPOKENWORD_02272025_2423177&amp;cid=CS-BENZ-FT-spoken_word-2423177" style="font-weight:bold">Today, See These 5 Potential Home Runs &gt;&gt;</a></p>
<p>&nbsp;</p>
<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_SPOKENWORD_2423177&amp;cid=CS-BENZ-FT-spoken_word-2423177" target="_blank">Click to get this free report</a></p>
<p>
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=APH&amp;ADID=SYND_BENZ_TCK_SPOKENWORD_2423177_APH&amp;cid=CS-BENZ-FT-spoken_word-2423177">Amphenol Corporation (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/aph#NYSE">APH</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CRWD&amp;ADID=SYND_BENZ_TCK_SPOKENWORD_2423177_CRWD&amp;cid=CS-BENZ-FT-spoken_word-2423177">CrowdStrike (CRWD): Free Stock Analysis Report</a></p>
<p><a href="https://www.zacks.com/commentary/2423177/will-yearend-2025-stock-returns-show-up?cid=CS-BENZ-FT-spoken_word-2423177">This article originally published on Zacks Investment Research (zacks.com).</a></p>
<p><a href="https://www.zacks.com/">Zacks Investment Research</a></p>


Equities

Markets

Will Year-end 2025 Stock Returns Show Up?

AAOI

Applied Optoelectronics shares are trading lower. The stock may be trading on continued weakness after the company issued Q1 adjusted EPS guidance below estimates on Wednesday.

HRTX

Heron Therapeutics shares are trading higher following better-than-expected Q4 financial results.

CSTL

Castle Biosciences shares are trading lower. The company reported Q4 financial results.

<p><strong>J.P. Morgan </strong>analyst Matthew R. Boss reiterated an <a target="_blank" href="https://www.benzinga.com/quote/GOLF/analyst-ratings" rel="noreferrer noopener">Underweight rating </a>on the shares of <strong>Acushnet Holdings Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) with a price forecast of $64.00.</p>
<p>GOLF posted an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44001386/acushnet-holdings-corp-announces-full-year-and-fourth-quarter-2024-financial-results" rel="noreferrer noopener">adjusted EBITDA of $12 million</a> for the fourth quarter, aligning closely with consensus estimates.</p>
<p>The analyst noted that the revenue growth of 7.8% fell short of the Street&#8217;s +9.9% expectations but was partially offset by a 300 basis point improvement in gross margin.</p>
<p>The analyst highlighted that the management provided FY25 adjusted EBITDA guidance of $405 million &#8211; 420 million (compared to the Street&#8217;s $412 million), expecting sales growth of 1.1% &#8211; 3.2% year-over-year, which is below the Street&#8217;s forecast of 3.8%, with modest gross margin growth offset by SG&amp;A leverage.</p>
<p>According to the analyst, in the near term, first-quarter sales are projected to decrease year-over-year due to several factors: the Pro V1/V1X launch expected to be more concentrated in the second quarter, tougher year-over-year comparisons in the first quarter, and foreign exchange headwind.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/44042800/plug-power-ties-executive-compensation-plan-to-stock-performance" rel="noreferrer noopener">Plug Power&#8217;s High-Stakes Move: Executives Can Take Up To 75% Of Pay In Company Stock</a></strong></p>
<p>By segment, management indicated that growth in the golf ball category is expected to be front-loaded in the first half, driven by the Pro V1/V1X launch, while growth in golf clubs is anticipated to be back-loaded in the second half due to the introduction of new irons.</p>
<p>The analyst models first quarter FY25 reported sales to decline 3.1% y/y, 700 basis points below the Street at 3.9% growth.</p>
<p>Crucially, management highlighted that the adjusted EBITDA outlook accounts for the anticipated negative effects of foreign exchange but excludes the impact of recently imposed tariffs.</p>
<p>With GOLF sourcing 6% of its cost of goods sold from China and having limited exposure to Mexico and Canada, the 10% additional tariff on China is expected to create a $7 million headwind, which is not yet reflected in the guidance, the analyst quipped.</p>
<p>The analyst sees downside based on the valuation multiple and the 2026 EBITDA projection, which suggests that the shares are overpriced compared to their current trading levels.</p>
<p>For the next few years, the analyst views GOLF&#8217;s opex investment cycle as a limitation to bottom-line growth, leading to flat EBITDA and low single-digit earnings per share growth, despite having &#8220;best-in-class&#8221; brands like Titleist and FootJoy, which hold leading market shares and target the &#8220;dedicated&#8221; golfer.</p>
<p><strong>Price Action</strong>: GOLF shares are trading lower by 1.62% at $63.83 at last check Friday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/25/02/44018649/spacex-rocket-launches-intuitive-machines-athena-lander-details" target="_blank" rel="noreferrer noopener">SpaceX Rocket Launches Intuitive Machines&#8217; Athena Lander: Details</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Analyst Color

News

Price Target

Reiteration

Analyst Ratings

General

GOLF

J.P. Morgan Flags Overvaluation In Acushnet—EBITDA Outlook Suggests Limited Upside

NVAX

Novavax shares are trading higher after the company reported better-than-expected Q4 revenue results.

ARLO

Arlo Technologies shares are trading higher. The company issued Q1 adjusted EPS guidance with its midpoint above estimates.

<p>The U.S. administration again expressed concerns over <strong>Huawei Technologies&#8217; </strong>access to <strong>Taiwan Semiconductor Manufacturing Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)&nbsp;chips, signifying continued geopolitical tensions over possessing <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence semiconductor technology</a>.</p>
<p>Recently, U.S. President Donald Trump&#8217;s export policy leader nominee, Jeffrey Kessler, highlighted concerns to Reuters over reports citing Taiwan Semiconductor-produced chips that went to China&#8217;s Huawei.</p>
<p>Kessler emphasized the Commerce Department&#8217;s Bureau of Industry and Security&#8217;s use of stricter penalties in cases of regulatory violations.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/tech/25/02/44019698/amazon-unveils-ocelot-quantum-chip-after-microsoft-aims-to-slash-error-correction-costs-by-90" rel="noreferrer noopener">Amazon Unveils Ocelot Quantum Chip After Microsoft, Aims to Slash Error Correction Costs by 90%</a></em></p>
<p>Taiwan Semiconductor client <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dominates the AI chip market as Huawei struggles to&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china" rel="noreferrer noopener">match CUDA&#8217;s efficiency</a>.</p>
<p>Washington restricted erstwhile smartphone giant Huawei&#8217;s exposure to advanced semiconductor technology in 2019, citing national security threats.</p>
<p>In October, a Canadian tech research firm, <strong>TechInsights</strong>, reportedly found a banned Taiwan Semiconductor chip in Huawei&#8217;s 910B AI processor.</p>
<p>Taiwan Semiconductor and Huawei professed their compliance with regulatory policies. Additionally, Taiwan Semiconductor suspended shipments to China-based chip designer <strong>Sophgo</strong>; shortly after, the U.S. imposed sanctions on Taiwan Semiconductor chip shipments to Chinese customers.</p>
<p>China <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">verbally attacked Taiwan</a> for surrendering its semiconductor industry to the U.S. for political support against China as Taiwan&#8217;s government relies on U.S. military support despite any defense treaty.</p>
<p>Since his presidential campaign, U.S. President Donald Trump has criticized Taiwan for allegedly stealing American semiconductor business and promised action against the country. Trump has also threatened retaliatory tariffs because of Taiwan&#8217;s trade surplus with the US.</p>
<p><a target="_blank" href="https://www.benzinga.com/25/02/43727973/taiwan-semiconductor-eyes-us-expansion-amid-taiwans-push-for-bigger-investments-and-advanced-chip-production" rel="noreferrer noopener">Taiwan reportedly promised</a> to boost U.S. trade and defense ties, addressing Trump&#8217;s chip concerns. Taiwan Semiconductor remains committed to its $65 billion investment in Arizona fabs.</p>
<p>Taiwan Semiconductor spent over $17 billion on advanced chips and packaging as it pushes for a global AI chip alliance. <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">Taiwan also maintained</a> that although it says Taiwan Semiconductor needs government approval for overseas joint ventures, the country allows advanced chip production outside China.</p>
<p><strong>Price Action:</strong> TSM stock is down 1.05% at $179.18 at the last check Friday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/emerging-markets/25/02/44017638/chinas-baidu-and-catl-team-up-to-build-next-gen-driverless-evs-integrating-advanced-battery-and-chassis-tech" target="_blank" rel="noreferrer noopener">China&#8217;s Baidu And CATL Team Up To Build Next-Gen Driverless EVs, Integrating Advanced Battery And Chassis Tech</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Politics

Tech

Media

NVDA

Taiwan Semi Faces Geopolitical Strain Due To US Scrutiny On Huawei's Chip Access

FIGS

FIGS shares are trading lower. The company reported Q4 financial results.

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count 489 Vs 488 Prior; U.S. Baker Hughes Total Rig Count 593 Vs 592 Prior

IHRT

IHeartMedia shares are trading lower after the company reported Q4 financial results and missed its EPS and sales estimates.

FANG

TRIP

CNBC Halftime Report Final Trades: Salesforce, TripAdvisor, The Walt Disney Company, Diamondback Energy

<p>Ratings for Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Portillos, revealing an average target of $14.0, a high estimate of $17.00, and a low estimate of $11.00. This current average has not changed from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740765682_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Portillos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Portillos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Portillos compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Portillos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Portillos's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PTLO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Portillos analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Portillos</h2>
<p>Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.</p>
<h3>Understanding the Numbers: Portillos's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Portillos's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-1.73%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Portillos's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.1%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Portillos's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.88%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Portillos's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.76%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.49</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PTLO

Where Portillos Stands With Analysts

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>IBM</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IBM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 22 uncommon options trades for IBM.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 36%, bearish.</p>
<p>Out of all of the special options we uncovered, 13 are puts, for a total amount of $760,681, and 9 are calls, for a total amount of $491,849.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $390.0 for IBM over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for IBM's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across IBM's significant trades, within a strike price range of $160.0 to $390.0, over the past month.</p>
<h3>IBM Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740765679_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.4</td>
<td>$5.0</td>
<td>$5.4</td>
<td>$250.00</td>
<td>$135.0K</td>
<td>2.5K</td>
<td align="right">252</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$5.9</td>
<td>$5.45</td>
<td>$5.9</td>
<td>$250.00</td>
<td>$119.5K</td>
<td>169</td>
<td align="right">264</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$36.4</td>
<td>$34.85</td>
<td>$35.5</td>
<td>$260.00</td>
<td>$106.5K</td>
<td>432</td>
<td align="right">8</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$30.0</td>
<td>$29.3</td>
<td>$29.81</td>
<td>$275.00</td>
<td>$98.8K</td>
<td>50</td>
<td align="right">33</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$94.35</td>
<td>$90.95</td>
<td>$93.04</td>
<td>$160.00</td>
<td>$93.0K</td>
<td>473</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About IBM</h3>
<p>IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which include 95% of all Fortune 500 companies. Primary products include its mainframes, Red Hat software, transaction processing software, and IT consulting.</p>
<p>In light of the recent options history for IBM, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>IBM's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,211,049, with IBM's price down by -1.8%, positioned at $248.68.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 54 days.</li>
</ul>
<h3>Professional Analyst Ratings for IBM</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $272.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on IBM, which currently sits at a price target of $228.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for IBM, targeting a price of $270.<br />
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for IBM, targeting a price of $276.<br />
&#x2A; An analyst from Oppenheimer has revised its rating downward to Outperform, adjusting the price target to $320.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on IBM, which currently sits at a price target of $270. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for IBM, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Check Out What Whales Are Doing With IBM

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Acadia Healthcare Co</strong>.</p>
<p>Looking at options history for Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 20% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $294,214 and 3, calls, for a total amount of $213,245.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $35.0 for Acadia Healthcare Co over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Acadia Healthcare Co stands at 612.0, with a total volume reaching 6,410.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Acadia Healthcare Co, situated within the strike price corridor from $30.0 to $35.0, throughout the last 30 days.</p>
<h3>Acadia Healthcare Co Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740765673_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$2.0</td>
<td>$3.0</td>
<td>$30.00</td>
<td>$74.7K</td>
<td>10</td>
<td align="right">503</td>
</tr>
<tr>
<td>ACHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.4</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$35.00</td>
<td>$71.3K</td>
<td>1.2K</td>
<td align="right">935</td>
</tr>
<tr>
<td>ACHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.0</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$30.00</td>
<td>$70.9K</td>
<td>10</td>
<td align="right">254</td>
</tr>
<tr>
<td>ACHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$30.00</td>
<td>$67.5K</td>
<td>10</td>
<td align="right">871</td>
</tr>
<tr>
<td>ACHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$35.00</td>
<td>$56.0K</td>
<td>1.2K</td>
<td align="right">506</td>
</tr>
</tbody>
</table>
</p>
<h3>About Acadia Healthcare Co</h3>
<p>Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.</p>
<p>In light of the recent options history for Acadia Healthcare Co, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Acadia Healthcare Co</h3>
<ul>
<li>Currently trading with a volume of 3,278,446, the ACHC's price is down by -23.92%, now at $30.63. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Acadia Healthcare Co</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $39.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $35.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Acadia Healthcare Co, maintaining a target price of $44. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Acadia Healthcare Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


ACHC

Market Whales and Their Recent Bets on ACHC Options

<p>Across the recent three months, 6 analysts have shared their insights on Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $58.83, along with a high estimate of $62.00 and a low estimate of $53.00. Witnessing a positive shift, the current average has risen by 7.3% from the previous average price target of $54.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740765672_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Skyward Specialty among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Skyward Specialty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Skyward Specialty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Skyward Specialty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SKWD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Skyward Specialty analyst ratings.</strong></a></p>
<h2>Delving into Skyward Specialty's Background</h2>
<p>Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.</p>
<h3>Understanding the Numbers: Skyward Specialty's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Skyward Specialty's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.78%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Skyward Specialty's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>4.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Skyward Specialty's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.81%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Skyward Specialty's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.39%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.15</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SKWD

Deep Dive Into Skyward Specialty Stock: Analyst Perspectives (6 Ratings)

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Applied Mat</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMAT, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 46 uncommon options trades for Applied Mat.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 52% bullish and 36%, bearish.</p>
<p>Out of all of the special options we uncovered, 33 are puts, for a total amount of $2,179,215, and 13 are calls, for a total amount of $722,211.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $85.0 to $210.0 for Applied Mat over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Applied Mat options trades today is 747.42 with a total volume of 3,459.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Applied Mat's big money trades within a strike price range of $85.0 to $210.0 over the last 30 days.</p>
<h3>Applied Mat Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740765668_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$12.3</td>
<td>$11.6</td>
<td>$11.8</td>
<td>$130.00</td>
<td>$369.3K</td>
<td>52</td>
<td align="right">313</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/28/25</td>
<td>$8.0</td>
<td>$7.75</td>
<td>$7.75</td>
<td>$160.00</td>
<td>$174.3K</td>
<td>81</td>
<td align="right">256</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$7.45</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$165.00</td>
<td>$157.5K</td>
<td>1.1K</td>
<td align="right">302</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$105.00</td>
<td>$107.6K</td>
<td>1.7K</td>
<td align="right">300</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.6</td>
<td>$10.5</td>
<td>$10.6</td>
<td>$135.00</td>
<td>$107.0K</td>
<td>675</td>
<td align="right">148</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Mat</h3>
<p>Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.</p>
<p>In light of the recent options history for Applied Mat, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Applied Mat</h3>
<ul>
<li>Currently trading with a volume of 2,982,578, the AMAT's price is down by -0.12%, now at $156.46. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>What Analysts Are Saying About Applied Mat</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $205.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham persists with their Buy rating on Applied Mat, maintaining a target price of $195.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Applied Mat with a target price of $190.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Applied Mat, targeting a price of $202.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Applied Mat, which currently sits at a price target of $235. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Applied Mat with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


AMAT

Looking At Applied Mat's Recent Unusual Options Activity

<p>In the latest quarter, 5 analysts provided ratings for PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for PENN Entertainment, revealing an average target of $24.2, a high estimate of $27.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 8.04% increase from the previous average price target of $22.40.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740765643_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of PENN Entertainment by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Joseph Greff</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PENN Entertainment. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PENN Entertainment compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of PENN Entertainment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of PENN Entertainment's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PENN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on PENN Entertainment analyst ratings.</strong></a></p>
<h2>All You Need to Know About PENN Entertainment</h2>
<p>Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 89% of total sales in 2023; 11% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.</p>
<h3>Financial Insights: PENN Entertainment</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> PENN Entertainment's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>1.22%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> PENN Entertainment's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-2.24%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.2%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> PENN Entertainment's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.24%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> PENN Entertainment's debt-to-equity ratio is below the industry average. With a ratio of <b>3.69</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PENN

Expert Outlook: PENN Entertainment Through The Eyes Of 5 Analysts

Press Releases

Novocure Reports Third Quarter 2024 Financial Results

Novocure Appoints Christoph Brackmann as Chief Financial Officer

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure to Participate in Upcoming Investor Conferences

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Comments

NovoCure

Noticias

Últimas noticias sobre NovoCure (NASDAQ:NVCR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL